scholarly journals Trastorno psicótico delirante, consumo de tóxicos y asesinato con alevosía y ensañamiento

2021 ◽  
Vol 2 (4) ◽  
pp. 5505-5512
Author(s):  
Bernat-Noël Tiffon Nonis
Keyword(s):  
Antipsychotic Medication ◽  
Paranoid Schizophrenia ◽  
Forensic Interviews ◽  
Treatment Abandonment

Se ilustra un caso de asesinato perpetrado por un sujeto afecto de esquizofrenia paranoide y, por cuyo momento de perpetrarse los hechos, presentaba una crisis psicótica aguda en ausencia de medicación antipsicótico por abandono del tratamiento. Se describe la fenomenología clínico-sintomatológica del perpetrador y del tipo de contenido de pensamiento psicótico-paranoide que mostraba al momento de celebrarse las entrevistas psicológicos-forenses.   A case of murder perpetrated by a subject affected by paranoid schizophrenia and, at the time of the perpetration, presenting an acute psychotic crisis in the absence of antipsychotic medication due to treatment abandonment, is illustrated. The clinical-symptomatological phenomenology of the perpetrator and the type of psychotic-paranoid thought content he showed at the time of the psychological-forensic interviews are described.

Delusional psychotic disorder, substance use and murder with alevosia and cruelty

2021 ◽  
Vol 2 (3) ◽  
pp. 4544-4551
Author(s):  
Bernat-Noël Tiffon Nonis
Keyword(s):  
Substance Use ◽  
Psychotic Disorder ◽  
Antipsychotic Medication ◽  
Paranoid Schizophrenia ◽  
Forensic Interviews

ABSTRACT A case of murder perpetrated by a subject with paranoid schizophrenia is illustrated and, at the time of the events, he presented an acute psychotic crisis in the absence of antipsychotic medication due to abandonment of treatment. The clinical-symptomatological phenomenology of the perpetrator and the type of psychotic-paranoid thought that he showed at the time of the psychological-forensic interviews are described.   RESUMEN Se expone un caso de asesinato perpetrado por un sujeto con esquizofrenia paranoide que, en el momento de los hechos, presentaba una crisis psicótica aguda en ausencia de medicación antipsicótica por abandono del tratamiento. Se describe la fenomenología clínico-sintomatológica del agresor y el tipo de pensamiento psicótico-paranoide que mostró en el momento de las entrevistas psicológico-forenses.

Cognitive Dissonance in the Treatment of Paranoid Schizophrenia

1995 ◽  
Vol 9 (4) ◽  
pp. 267-278 ◽  
Author(s):  
Joseph Levine ◽  
Yoram Barak ◽  
Natan Caspi
Keyword(s):  
Partial Response ◽  
Cognitive Dissonance ◽  
Antipsychotic Medication ◽  
Paranoid Schizophrenia ◽  
Symptomatic Relief ◽  
Group Pressure ◽  
Basic Characteristics ◽  
Difficult Challenge ◽  
Basic Axiom ◽  
Two Alternatives

Paranoid thinking is often well organized, systemized and detailed so that treating a paranoid patient is a difficult challenge. It is suggested that cognitive dissonance, once created, may cause a person to change his cognitions in order to lower or eliminate it. The treatment of a paranoid schizophrenic is presented wherein by introducing strong group pressure the patient accepted an axiom, which created dissonance with his paranoid content. This axiom was “A wise man sees more than two alternatives in any given situation.” Therefore, by stepwise pacing, alternative evaluations of affect “free” situations were made by the patient using the accepted basic axiom. This technique was gradually used with the patient’s paranoid content, and later on with basic characteristics underlying the paranoid system. The patient exhibited curiosity and a willingness to investigate his paranoid inner state according to the new accepted axiom, and a significant symptomatic relief was seen within a few days, in contrast to past hospitalizations where only partial response to antipsychotic medication was noted. Research is needed in order to examine the effectiveness of this mode of treatment.

Metabolic syndrome in schizophrenia -impact of antipsychotic medication

2011 ◽  
Vol 26 (S2) ◽  
pp. 1255-1255
Author(s):  
T.M.-S. Maria-Silvia
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Family History ◽  
Antipsychotic Medication ◽  
Paranoid Schizophrenia ◽  
Personal Hygiene ◽  
Psychotic Symptoms ◽  
Psychotic Behavior ◽  
Diet And Lifestyle ◽  
Almost Continuous

Metabolic syndrome generally includes some or all of the following: elevated blood pressure, abdominal obesity, diabetes or “prediabetes” (impaired glucose tolerance, impaired fasting glucose or insulin resistance), dyslipidemia (high levels of triglycerides and/or HDL), and inflammatory markersP.S. a 34 year old, diagnosed with Paranoid schizophrenia. The patient comes from a disorganised family. The disease started at 18 years with psychotic symptoms - delirious, psychotic behavior, aggression, neglect of personal hygiene. He received almost continuous antipsychotic medication. In recent years received the second generation antipsychotic medication. Under this medication increased weight reaching 160 kg in weight. The most significant weight gain occurred in recent years under neuroleptic medication with clozapinum. Hypertension (max 200/120) appeared as a complication of increased weight, requiring antihypertensive medication. Has not other endocrine problems. Laboratory values increased cholesterol, triglyceride, and lipid. Glycemia remained normal. In the last six months patient received amisulpiridum 800 mg/day. In same conditions of life the patient has lost 40 kg in weight reaching 140 kg. Family history- mother obesity and HTA;Weight and (BMI) initially 160kg/180 cm then 120 kg/180 cm;Waist circumference 140 cm;Blood pressure initially 200/120 mm Hg then160 /110 mmhg;Fasting lipids increased,glucose normal Conclusion: Assessment of risk factors is necessary before prescription of antipsychotics. Especially weight, BMI, family history for obesity, and ethnicity should be evaluated. People taking antipsychotics that increase the risk of MetS should be educated on this subject. They should be advised about their diet and lifestyle, about how to recognize symptoms of MetS and its consequences.

scholarly journals Antipsychotic Medication Use Delays Diagnosis of Acromegaly

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A574-A574
Author(s):  
Matthew Norman Rosner ◽  
Ambika Rao
Keyword(s):  
Differential Diagnosis ◽  
Visual Field ◽  
Antipsychotic Medication ◽  
Prolactin Level ◽  
Paranoid Schizophrenia ◽  
Field Testing ◽  
Oral Glucose ◽  
Visual Field Testing ◽  
Lost To Follow Up

Abstract Background: Elevated prolactin level from use of antipsychotic medication masked the diagnosis of acromegaly. Clinical Case: A 29-year old woman presented with galactorrhea, metrorrhagia, menorrhagia, 50 lb. weight gain, hirsutism, insomnia, and breast engorgement for one year. She was evaluated by gynecology and treated with a combination estrogen/progesterone pill, and then switched to a patch. For several years she had been on haloperidol and various phenothiazine medications for paranoid schizophrenia. Initial evaluation included elevated prolactin level of 94.46 ng/ml (5.2-26.25 ng/mL). Differential diagnosis of PCOS versus medication induced hyperprolactinemia was considered. Patient was started on metformin and referred to nutrition for weight management. MRI scan ordered by her primacy care physician revealed a 13 x 12 x 10 mm pituitary mass with intrinsic mixed density and homogenous enhancement. Visual field testing revealed no deficits. On further testing: IgF-1 432 ng/ml (53-331 ng/ml), TSH 0.85 uIU/mL (0.35-4.94 IUI/ml), ACTH 22 pg/mL (6-50 pg/ml), cortisol 7.7 ug/dl (4.3-22.4 mcg/dl). Differential diagnosis of stalk compression versus functioning adenoma was considered and cabergoline was initiated after she was seen by neurosurgery and declined surgical intervention. She was noncompliant with cabergoline. Surveillance over next two years showed no increase in tumor size on MRI or change in hormone levels. She was then lost to follow up for a year and presented with increased diaphoresis and swelling of her hands. Prolactin three years after diagnosis decreased to 50.59 ng/mL and IgF-1 to 639 ng/ml. She was then referred to endocrinology. Oral glucose tolerance test did not suppress growth hormone below 1.9 ng/ml. Her cortisol suppressed to 0.1 mcg/dl with 1 mg dexamethasone. A diagnosis of Acromegaly was confirmed. She was referred for neurosurgical evaluation and scheduled for transsphenoidal hypophysectomy. She failed to arrive for scheduled surgery. Repeat MRI five years after diagnosis showed a 13 x 16 x 20 mm pituitary adenoma with IgF-1 level of 1011 ng/ml. Octreotide LAR 20 mg monthly was initiated. After two months of injections: prolactin 69.36 ng/ml, IgF-1 778 ng/ml. Repeat visual field testing showed mild constriction in the superior and inferior temporal fields. Patient was scheduled for MRI and surgical procedure but was lost to follow-up. Conclusion: Elevation in prolactin levels in conjunction with antipsychotic medications and diagnosis of schizophrenia masked the early diagnosis of Acromegaly in this patient.

scholarly journals Maintenance Electroconvulsive Therapy in a Patient with Treatment-Resistant Paranoid Schizophrenia and Comorbid Epilepsy

2012 ◽  
Vol 2012 ◽  
pp. 1-3 ◽  
Author(s):  
Beppe Micallef-Trigona ◽  
Joseph Spiteri
Keyword(s):  
Drug Treatment ◽  
Electroconvulsive Therapy ◽  
Antipsychotic Medication ◽  
Maintenance Treatment ◽  
Therapeutic Response ◽  
Paranoid Schizophrenia ◽  
Treatment Resistant ◽  
Maintenance Ect ◽  
Antipsychotic Drug Treatment ◽  
Atypical Antipsychotic Medication

The treatment of choice for acute schizophrenia is antipsychotic drug treatment and electroconvulsive therapy (ECT) and should only be considered as an option for treatment-resistant schizophrenia, where treatment with clozapine has already proven ineffective or intolerable. The use of ECT as a maintenance treatment for patients with schizophrenia and comorbid epilepsy is uncommon as scant evidence exists to support this. We describe a patient with a serious case of paranoid schizophrenia and comorbid epilepsy who had not responded to typical and atypical antipsychotic medication, but responded remarkably to acute ECT and required maintenance ECT to sustain a positive therapeutic response.

Improved Functioning in a Woman with Schizophrenia on Exclusive Therapy with Oestrogen Pills

2002 ◽  
Vol 10 (4) ◽  
pp. 403-404 ◽  
Author(s):  
Mosunmola Tunde-Ayinmode ◽  
Ashok Singh ◽  
Karen Marsden
Keyword(s):  
Clinical Trials ◽  
Case Report ◽  
Oral Contraceptive ◽  
Social Functioning ◽  
Antipsychotic Medication ◽  
Therapeutic Potential ◽  
Paranoid Schizophrenia ◽  
Oral Contraceptive Pill ◽  
Oestrogen Therapy ◽  
Contraceptive Pill

Objective: To highlight the therapeutic potential of oestrogen in schizophrenia and raise awareness about the need for more clinical trials. Method: Case Report. Results: The case concerns a woman suffering from chronic paranoid schizophrenia, who complied poorly with antipsychotic medication and had severely impaired psychological and social functioning. Oestrogen therapy in the form of an oral contraceptive pill (brevinor- norethisterone/ ethinyloestradiol) was used with effect. Conclusions: Oestrogen therapy shows promise in select cases in the treatment of schizophrenia and warrants further study.

Sign in / Sign up

Export Citation Format

Share Document